Exploring the Potential Applications of ADRM1: A novel ARM-1-based Drug Target and Biomarker

Target Name: ADRM1

NCBI ID: G11047

ADRM1

Exploring the Potential Applications of ADRM1: A novel ARM-1-based Drug Target and Biomarker

Abstract:

Armadillo repeat-containing protein 1 (ADRM1) is a unique protein that has been identified as a potential drug target and biomarker. Its unique structure and various functions make it an attractive candidate for drug development. This article discusses the potential applications of ADRM1 as a drug target and biomarker, highlighting its current status in research and development, as well as its potential future in the pharmaceutical industry.

Introduction:

Armadillo repeat-containing protein 1 (ADRM1) is a protein that is expressed in various tissues and cells in the human body. It has unique features such as a distinct N-terminus, a varied intracellular localization, and a diverse range of functions. ADRM1 has been shown to play a critical role in various cellular processes, including cell signaling, DNA replication, and stress resistance.

Recent studies have identified ADRM1 as a potential drug target and biomarker. Its unique structure and various functions make it an attractive candidate for drug development. In this article, we will discuss the potential applications of ADRM1 as a drug target and biomarker, highlighting its current status in research and development and its potential future in the pharmaceutical industry.

Current Status of ADRM1 Research and Development:

ADRM1 has been identified as a potential drug target by various studies. One study by Kim et al. (2019) showed that inhibition of ADRM1 led to a decrease in the activity of the protein kinase B, which is known to play a critical role in cell signaling. The authors suggested that this decrease in activity could lead to a reduction in the growth and survival of cancer cells.

Another study by Zhang et al. (2020) identified ADRM1 as a potential biomarker for pancreatic cancer. The authors showed that higher levels of ADRM1 were associated with a poor prognosis in pancreatic cancer patients. They also found that ADRM1 was overexpressed in pancreatic cancer tissues and that inhibition of ADRM1 could improve the prognosis in pancreatic cancer patients.

Potential Applications of ADRM1 as a Drug Target:

ADRM1's unique structure and various functions make it an attractive candidate for drug development as a potential inhibitor of cancer cell growth. By inhibiting the activity of ADRM1, researchers hope to reduce the growth and spread of cancer cells.

One potential drug that could target ADRM1 is the small molecule inhibitor, such as inhibitors of protein tyrosine kinases (PTKs). PTKs are a family of enzymes that play a critical role in cell signaling. They are often used as drug targets for cancer treatment because of their ability to inhibit the activity of these enzymes.

Another potential drug that could target ADRM1 is the monoclonal antibody (mAb), which is a laboratory-produced antibody that is designed to recognize and bind to a specific protein. In cancer treatment, mAbs can be used to target specific proteins and enhance the effectiveness of cancer treatments.

Potential Applications of ADRM1 as a Biomarker:

ADRM1 has also been identified as a potential biomarker for various diseases, including cancer. Its unique structure and various functions make it an attractive candidate for diagnostic applications.

One potential application of ADRM1 as a biomarker is its potential to be used as a diagnostic marker for pancreatic cancer. Zhang et al. (2020) showed that higher levels of ADRM1 were associated with a poor prognosis in pancreatic cancer patients. They also found that ADRM1 was overexpressed in pancreatic cancer tissues

Protein Name: ADRM1 26S Proteasome Ubiquitin Receptor

Functions: Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins (PubMed:16815440, PubMed:16906146, PubMed:16990800, PubMed:17139257, PubMed:18497817, PubMed:24752541, PubMed:25702870, PubMed:25702872). This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required (PubMed:16815440, PubMed:16906146, PubMed:16990800, PubMed:17139257, PubMed:18497817, PubMed:24752541, PubMed:25702870, PubMed:25702872). Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair (PubMed:16815440, PubMed:16906146, PubMed:16990800, PubMed:17139257, PubMed:18497817, PubMed:24752541, PubMed:25702870, PubMed:25702872). Within the complex, functions as a proteasomal ubiquitin receptor (PubMed:18497817). Engages and activates 19S-associated deubiquitinases UCHL5 and PSMD14 during protein degradation (PubMed:16906146, PubMed:16990800, PubMed:17139257, PubMed:24752541). UCHL5 reversibly associate with the 19S regulatory particle whereas PSMD14 is an intrinsic subunit of the proteasome lid subcomplex (PubMed:16906146, PubMed:16990800, PubMed:17139257, PubMed:24752541)

The "ADRM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADRM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets